Levetiracetam Teva

RSS

levetiracetam

Authorised
This medicine is authorised for use in the European Union.

Overview

Levetiracetam Teva is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. Secondary generalisation occurs when the overactivity later reaches the whole brain.

Levetiracetam Teva can also be used as an add-on to other epilepsy medicines to treat:

  • partial-onset seizures with or without generalisation in patients from 1 month of age;
  • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
  • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to be inherited).

Levetiracetam Teva contains the active substance levetiracetam and is a ‘generic medicine’. This means that Levetiracetam Teva contains the same active substance and works in the same way as  a ‘reference medicine’ already authorised in the EU called Keppra. For more information on generic medicines, see the question-and-answer document here.

This EPAR was last updated on 19/08/2021

Authorisation details

Product details
Name
Levetiracetam Teva
Agency product number
EMEA/H/C/002316
Active substance
levetiracetam
International non-proprietary name (INN) or common name
levetiracetam
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX14
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva B.V.
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
25/08/2011
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

17/06/2021 Levetiracetam Teva - EMEA/H/C/002316 - IB/0035

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Nervous sytem

Therapeutic indication

Levetiracetam Teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam Teva is indicated as adjunctive therapy:

  • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;
  • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;
  • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Assessment history

How useful was this page?

Add your rating
Average
1 rating